Selected Alkylating Agents Can Overcome Drug Tolerance of G-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

Pajic, Marina; Blatter, Sohvi Tuulikki; Guyader, Charlotte; Gonggrijp, Maaike; Kersbergen, Ariena; Küçükosmanoğlu, Aslι; Sol, Wendy; Drost, Rinske; Jonkers, Jos; Borst, Piet; Rottenberg, Sven (2017). Selected Alkylating Agents Can Overcome Drug Tolerance of G-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. Clinical cancer research, 23(22), pp. 7020-7033. American Association for Cancer Research 10.1158/1078-0432.CCR-17-1279

[img] Text
7020.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.We studied responses to various mono- and bifunctional alkylating agents in a genetically engineered mouse model for-mutant breast cancer. Because of the large intragenic deletion of thegene, no restoration of BRCA1 function is possible, and therefore, no BRCA1-dependent acquired resistance occurs. To characterize the cell-cycle stage from whichmammary tumors arise after cisplatin treatment, we introduced the fluorescent ubiquitination-based cell-cycle indicator (FUCCI) construct into the tumor cells.Despite repeated sensitivity to the MTD of platinum drugs, the-mutated mammary tumors are not eradicated, not even by a frequent dosing schedule. We show that relapse comes from single-nucleated cells delaying entry into the S-phase. Such slowly cycling cells, which are present within the drug-naïve tumors, are enriched in tumor remnants. Using the FUCCI construct, we identified nonfluorescent G-like cells as the population most tolerant to platinum drugs. Intriguingly, these cells are more sensitive to the DNA-crosslinking agent nimustine, resulting in an increased number of multinucleated cells that lack clonogenicity. This is consistent with ourfinding that the nimustine MTD, among several alkylating agents, is the most effective in eradicating-mutated mouse mammary tumors.Our data show that targeting G-like cells is crucial for the eradication of BRCA1/p53-deficient tumor cells. This can be achieved with selected alkylating agents such as nimustine..

Item Type:

Journal Article (Original Article)

Division/Institute:

05 Veterinary Medicine > Research Foci > Host-Pathogen Interaction
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Animal Pathology
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)

UniBE Contributor:

Blatter, Sohvi Tuulikki and Rottenberg, Sven

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 630 Agriculture

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Achim Braun Parham

Date Deposited:

11 Jul 2018 17:02

Last Modified:

11 Jul 2018 17:02

Publisher DOI:

10.1158/1078-0432.CCR-17-1279

PubMed ID:

28821557

BORIS DOI:

10.7892/boris.112031

URI:

https://boris.unibe.ch/id/eprint/112031

Actions (login required)

Edit item Edit item
Provide Feedback